<< Back to News

New FDA Approval for BLINCYTO®

On March 29th, 2018 the U.S. Food and Drug Administration (FDA) granted approval to BLINCYTO® (blinatumomab) for the treatment of minimal residual disease (MRD)-positive B-cell precursor Acute Lymphoblastic Leukemia (ALL).  

The FDA approved Amgen’s supplemental Biologics License Application (sBLA) for BLINCYTO® based results from the BLAST study.  

For additional information on the approval, please click here to access the full Amgen press release. 

Please see below for the Indications and Important Safety Information for BLINCYTO®.

Complete information regarding dosing and administration, warnings, precautions, safety and efficacy, can be found in the full prescribing information by clicking here.